GCPII imaging and cancer

C. A. Foss, R. C. Mease, S. Y. Cho, H. J. Kim, M. G. Pomper

Research output: Contribution to journalReview articlepeer-review

Abstract

Glutamate carboxypeptidase II (GCPII) in the central nervous system is referred to as the prostate-specific membrane antigen (PSMA) in the periphery. PSMA serves as a target for imaging and treatment of prostate cancer and because of its expression in solid tumor neovasculature has the potential to be used in this regard for other malignancies as well. An overview of GCPII/PSMA in cancer, as well as a discussion of imaging and therapy of prostate cancer using a wide variety of PSMA-targeting agents is provided.

Original languageEnglish (US)
Pages (from-to)1346-1359
Number of pages14
JournalCurrent medicinal chemistry
Volume19
Issue number9
DOIs
StatePublished - Mar 2012

Keywords

  • PET
  • PSMA
  • Prostate-specific membrane antigen
  • SPECT
  • molecular imaging
  • prostate cancer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'GCPII imaging and cancer'. Together they form a unique fingerprint.

Cite this